BEAMBEAM
US • —
$34.32
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
+158.0% YoY
Gross Margin
—
Health Score
5/10
D/E Ratio
—
Confidence
LOW
Business Snapshot
Beam Therapeutics operates as a biotechnology company focused on precision genetic medicines through its base editing platform, which allows for precise modification of DNA without double-stranded breaks. The company primarily targets severe genetic diseases across therapeutic areas including sickle cell disease and liver disorders. Beam operates in the competitive gene editing market, a field that includes larger players like CRISPR Therapeutics and Intellia, positioning it as a niche technology leader given its proprietary base editing approach. The company's defining characteristic is its differentiated base editing technology, which offers theoretical safety advantages over traditional CRISPR-Cas9 editing. As of the provided data, the company's market cap and trailing twelve-month revenue figures are unavailable, constraining a full assessment of its financial scale.
Financial Health
Gross margin data is unavailable, preventing a full analysis of product-level profitability, while the net margin of -39.7% highlights that the company is deeply unprofitable on an earnings basis. The balance sheet appears conservative with a debt-to-equity ratio of 0.0x and a very strong current ratio of 13.09x, indicating ample short-term liquidity and no reliance on debt financing...
Risk Assessment
- VALUATION — The price-to-sales ratio of 21.85x is extremely high for a company with a net margin of -39.7%, implying the market is pricing in substantial future profitability that has not yet materialized.
- EARNINGS QUALITY — Net margin of -39.7% confirms the company is deeply unprofitable, and no earnings growth data is available to assess whether this is improving.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- DATA COMPLETENESS — Two core fundamental metrics (P/E, revenue, FCF) are unavailable, creating a fundamental data vacuum that significantly increases investment risk.
- LIQUIDITY — Despite a strong current ratio of 13.09x, the company's negative net margin suggests ongoing cash burn that will eventually deplete this liquidity cushion....
Gross margin data is unavailable, preventing a full analysis of product-level profitability, while the net margin of -39.7% highlights that the company is deeply unprofitable on an earnings basis. The balance sheet appears conservative with a debt-to-equity ratio of 0.0x and a very strong current ratio of 13.09x, indicating ample short-term liquidity and no reliance on debt financing. Free cash flow data is not available in this payload, making it impossible to assess whether the company is funding operations through cash generation or cash burn. The negative return on equity of -5.9% confirms that the company is not generating a profit on shareholder equity, which is common for early-stage biotechs. Overall, while the liquidity position is robust, the absence of revenue and FCF data creates significant uncertainty about the company's ability to fund its operations without future dilution.
- VALUATION — The price-to-sales ratio of 21.85x is extremely high for a company with a net margin of -39.7%, implying the market is pricing in substantial future profitability that has not yet materialized. - EARNINGS QUALITY — Net margin of -39.7% confirms the company is deeply unprofitable, and no earnings growth data is available to assess whether this is improving. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - DATA COMPLETENESS — Two core fundamental metrics (P/E, revenue, FCF) are unavailable, creating a fundamental data vacuum that significantly increases investment risk. - LIQUIDITY — Despite a strong current ratio of 13.09x, the company's negative net margin suggests ongoing cash burn that will eventually deplete this liquidity cushion.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives